CPRX
Catalyst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.49
+0.00%Price chart
Jun 18Jun 24Jun 29Jul 2Jul 8Jul 13Jul 16Jul 21
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
9.3x
Market Cap
$3.85B
MomentumView details →
1D Return
+0.00%
YTD Return
+34.92%
RSI (14)
70.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
9.3x
Market Cap
$3.85B
RSI (14)
70.2
MomentumView details →
1D Return
+0.00%
YTD Return
+34.92%
SummaryUpdated Mar 1, 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company founded in 2002 and headquartered in Coral Gables, Florida. The company went public in 2006 and focuses on developing and commercializing therapies for rare debilitating, chronic neuromuscular, and neurological diseases. Originally known as Catalyst Pharmaceutical Partners, Inc., the company changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Over the past two decades, Catalyst has evolved from a development-stage company to a profitable commercial enterprise with multiple marketed products generating nearly $500 million in annual revenue.
Similar companies
Latest newsMore news →
Chuck Royce reduced his fund's stake in Catalyst Pharmaceuticals during the second quarter of 2026, as disclosed in the 13F filing.21d agoAngelini Pharma completed its acquisition of Catalyst Pharmaceuticals, gaining ownership of Catalyst's product portfolio and strengthening its presence in the U.S. market.51d agoCatalyst Pharmaceuticals stockholders approved the merger with Angelini Pharma S.p.A. at a special meeting on July 8.56d ago